Danish drugmaker Novo Nordisk on Tuesday, November 11, cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters.

Wegovy’s highest dose of 2.4 mg will now cost 16,400 rupees ($186.59), compared with its earlier price of 24,389.06 rupees, the document sent by Novo to drug distributors showed.

Its lowest dose of 0.25 mg will sell at 10,850 rupees, compared with 16,260.94 rupees earlier, according to the document.

The move comes just days after rival Eli Lilly’s weight-loss therapy, Mounjaro, became India’s top-selling drug by value in October.

Wegovy’s active ingredient semaglutide goes off patent in India in March 2026, paving the way for generic players to enter the market.

Novo and Lilly are locked in a race for dominanc

See Full Page